Rohit Gosain/LinkedIn
Oct 27, 2025, 08:00
Rohit Gosain: Revumenib is Now FDA Approved for R/R AML with NPM1 Mutation
Rohit Gosain, Medical Director of Roswell Park Comprehensive Cancer Center, posted on LinkedIn:
“Revumenib is now FDA approved for R/R AML with NPM1 mutation (approved for KMT2A translocation previously).
– ORR 46.9%
– Response seen in all subgroups (comutations, previous HSCT, or high number of prior lines of Rx).”

Stay informed with Hemostasis Today.
-
Aug 26, 2026, 15:04Sequential Efgartigimod and Eltrombopag Achieve Durable Response in Refractory ITP – Platelets Journal
-
Aug 26, 2026, 14:46Holly O’Byrne: A Framework for Developing and Managing Prehospital Blood Programs
-
Aug 26, 2026, 14:32Eleftherios Mylonakis: Earlier Intervention, Better Risk Stratification, Stronger BP Control
-
Aug 26, 2026, 14:32Bringing ISTH 2026 Research to the Global Scientific Community
-
Aug 26, 2026, 14:18Thomas Dayspring: Prognostic Impact of Lp(a) Changes Following Statin Therapy in Patients with CAD
-
Aug 26, 2026, 14:17Khurram Nasir: Are We Debating the Wrong Thing About Research in Medical Training?
-
Aug 26, 2026, 14:15Nathan Connell: Why Format Free Publishing Still Demands Formatting?
-
Aug 26, 2026, 14:14Reza Shojaei: China’s Reliance on Imported Albumin Raises Global Plasma Security Concerns
-
Aug 26, 2026, 14:03Ahmad Masri: The Amyloid Depleter Revolution in ATTR-CM